ImmunityBio (IBRX) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
ImmunityBio (IBRX) has outperformed Vaxcyte (PCVX) over the past year, gaining 290.4% versus a gain of 59.9%. Over five years, PCVX leads with a +174.3% price change compared with +4.8% for IBRX. ImmunityBio is the larger company by market cap ($10.33 billion vs $9.96 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | PCVX |
|---|---|---|
| Share price | $9.75 | $66.96 |
| Market cap | $10.33B | $9.96B |
| 1-day change | +0.62% | +0.39% |
| YTD return | +392.93% | +45.12% |
| 1-year return | +290.40% | +59.92% |
| 5-year return | +4.84% | +174.31% |
| EPS (TTM) | $-0.97 | $-7.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | — |
| Revenue growth (YoY) | +668.31% | — |
| Net income (latest FY) | $-351.40M | $-766.63M |
| Gross margin | 99.34% | — |
| Operating margin | -226.00% | — |
| Net margin | -310.18% | — |
| 52-week high | $12.43 | $90.75 |
| 52-week low | $1.95 | $39.87 |
| Distance from 52-week high | -21.56% | -26.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +30.77% | +65.59% |
| Average volume | 10.26M | 1.50M |
| Shares outstanding | 1.06B | 148.81M |
| Employees | 684 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed PCVX by 230.5 percentage points over the past year.
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
IBRX vs PCVX FAQ
Which is bigger, ImmunityBio or Vaxcyte?
ImmunityBio (IBRX) is larger, with a market capitalization of $10.33B compared with $9.96B for Vaxcyte (PCVX).
Which stock has performed better over the past year, IBRX or PCVX?
IBRX returned +290.40% over the past 12 months, compared with +59.92% for PCVX (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.